TGTX News and Press, TG Therapeutics Inc.

2024-07-04 22:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-07-02 13:00:00 ET Summary 21 new analysts joined in June and are highlighted today. Each is introduced with some details on their first investment thesis on Seeking Alpha and their background. Analysts cover a range of sectors including biotech, technology, consumer staples, ...

2024-06-25 00:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-06-12 04:40:57 ET Summary TG Therapeutics is a small biotech company that sell ublituximab (a new anti-CD20 monoclonal antibody) for the treatment of multiple sclerosis (MS). Anti-CD20 class is the largest ($9bn) and only growing drug class in MS. Ublituximab is a third-in-cl...

2024-06-11 08:45:53 ET Palm Beach, FL – June 11, 2024 – FN Media Group News Commentary – In the last twenty years, the amount of people with multiple sclerosis (MS) in the United States has more than doubled. In 2000, it was estimated by the National Multipl...

NEW YORK, June 07, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Goldman Sachs 45 th Annual Global Healthcare Conference, being held at the Loews Miami Bea...

NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Jefferies Global Healthcare Conference, being held at the Marriott Marquis, in New York City o...

NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI ® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the...

NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple scl...

2024-05-25 10:24:03 ET More on AbbVie, Amgen, etc. Bristol Myers Squibb: 5.5% Yielder Has Been Crushed In What Could Be A Generational Buying Opportunity Why Gilead Sciences' 4.6% Yield Doesn't Make The Cut For Smart Investors Amgen Stock: Poised To Break Out (Techni...